Hydrogen sulfide and its donors: Novel antitumor and antimetastatic agents for liver cancer

Cell Signal. 2023 Jun:106:110628. doi: 10.1016/j.cellsig.2023.110628. Epub 2023 Feb 10.

Abstract

Hepatocellular carcinoma (HCC) is the sixth most frequent human cancer and the world's third most significant cause of cancer mortality. HCC treatment has recently improved, but its mortality continues to increase worldwide due to its extremely complicated and heterogeneous genetic abnormalities. After nitric oxide (NO) and carbon monoxide (CO), the third gas signaling molecule discovered is hydrogen sulfide (H2S), which has long been thought to be a toxic gas. However, numerous studies have proven that H2S plays many pathophysiological roles in mammals. Endogenous or exogenous H2S can decrease cell proliferation, promote apoptosis, block cell cycle, invasion and migration through various cellular signaling pathways. This review analyzes and discusses the recent literature on the function and molecular mechanism of H2S and H2S donors in HCC, so as to provide convenience for the scientific research and clinical application of H2S in the treatment of liver cancer.

Keywords: Hepatocellular carcinoma; Hydrogen sulfide; Hydrogen sulfide donors; Signaling pathway.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Carcinoma, Hepatocellular* / drug therapy
  • Humans
  • Hydrogen Sulfide* / metabolism
  • Hydrogen Sulfide* / pharmacology
  • Hydrogen Sulfide* / therapeutic use
  • Liver Neoplasms* / drug therapy
  • Mammals / metabolism
  • Nitric Oxide / metabolism
  • Signal Transduction / physiology

Substances

  • Hydrogen Sulfide
  • Nitric Oxide
  • Antineoplastic Agents